Transparency improvement agent for skin and food for improving transparency of skin

Abstract

According to the present invention, a transparency improvement agent for the skin includes an extract from a plant that contains a rosacyanin compound.

Description

Skin clarity enhancers and foods for improving skin clarity

[0001] The present disclosure relates to a skin clarity enhancer and a food product for improving skin clarity.

[0002] In recent years, people have become increasingly interested in beautiful skin. Translucent skin is one of the major factors for beautiful skin, and there is a growing demand for cosmetics and other products that can achieve translucent skin.

[0003] Various topical preparations have been developed for the purpose of improving skin clarity. For example, Patent Document 1 discloses a skin clarity improver containing an extract from yellow quince leaves and / or an extract from lotus germ as an active ingredient, and shows that the skin clarity is improved by inhibiting carbonylation of stratum corneum proteins.

[0004] Patent Publication No. 2012-41276

[0005] The inventors have conducted extensive research into new substances that can improve skin clarity. One aspect of the present disclosure is to provide a novel skin clarity improver.

[0006] One aspect of the present disclosure is a skin clarity enhancer, which comprises an extract from a plant containing a rosacyanin compound. In one aspect of the present disclosure, the improvement in skin clarity may be achieved by promoting blood circulation in the skin.

[0007] In one aspect of the present disclosure, the improvement of skin clarity may be achieved through a reduction in sebum secretion. In one aspect of the present disclosure, dullness of the skin may be improved by promoting blood circulation in the skin. In one aspect of the present disclosure, the reduction in sebum secretion may improve the visibility of pores in the skin.

[0008] In one aspect of the present disclosure, the composition may be administered orally. In one aspect of the present disclosure, the composition is a food product for improving skin clarity, the food product comprising the above-described skin clarity improver.

[0009] According to this configuration, a novel skin transparency improver is provided, which improves skin transparency, and more preferably improves skin transparency by promoting blood circulation in the skin and / or reducing sebum secretion.

[0010] 1 is a graph showing the results of visual evaluation of skin transparency. The graph shows the change (%) in skin transparency after 4 weeks of ingestion of the test product or control product in the test product intake group and the control product intake group, with skin transparency before the test taken as 100%. The change is expressed as mean ± standard error. The graph shows the results of measuring sebum volume. The graph shows the change (%) in sebum volume after 4 weeks of ingestion of the test product or control product in the test product intake group and the control product intake group, with sebum volume before the test taken as 100%. The change is expressed as mean ± standard error. The graph shows the results of measuring hemoglobin index. The graph shows the change (%) in hemoglobin index after 4 weeks of ingestion of the test product or control product in the test product intake group and the control product intake group, with hemoglobin index before the test taken as 100%. The change is expressed as mean ± standard error. The graph shows the results of measuring facial body surface temperature. The change in body surface temperature (%) after 4 weeks of ingestion of the test product or control product in the test and control groups is shown, with the body surface temperature before the test being taken as 100%. The change is expressed as the mean value ± standard error. ＊ ) in the test product intake group and the control product intake group. ＊ ) is taken as 100%, the redness of the skin after 4 weeks of taking the test product or the control product (a ＊) is shown. The changes are expressed as mean ± standard error. Graph showing the results of visual evaluation of dullness. Graph showing the change (%) in dullness after 4 weeks of ingestion of the test product or control product in the test product intake group and the control product intake group, when the dullness before the test is set to 100%. The changes are expressed as mean ± standard error. Graph showing the results of visual evaluation of darkening of pores. Graph showing the change (%) in darkening of pores after 4 weeks of ingestion of the test product or control product in the test product intake group and the control product intake group, when the dullness before the test is set to 100%. The changes are expressed as mean ± standard error. Graph showing the results of analysis of the total number of pores in replica images of the cheek. Graph showing the change (%) in the total number of pores after 4 weeks of ingestion of the test product or control product in the test product intake group and the control product intake group, when the total number of pores before the test is set to 100%. The changes are expressed as mean ± standard error. This is a graph showing the results of analyzing the contrast of pores in replica images of the cheek. The graph shows the change (%) in the contrast of pores after 4 weeks of ingestion of the test product or control product, with the contrast of pores before the test being set at 100%. The changes are expressed as mean ± standard error.

[0011] The skin clarity enhancer of the present disclosure comprises a plant extract containing a rosacyanin-type compound. Rosacyanin is a type of polyphenol discovered as a pigment in blue plants of the Rosaceae family. Examples of rosacyanin-type compounds include, but are not limited to, rosacyanin A1, rosacyanin B, and rosacyanin A2.

[0012] Examples of plants containing rosacyanin compounds include plants of the Rosaceae family, preferably plants of the Rosaceae family having a purple-blue color tone. In the present disclosure, plants of the Rosaceae family having a purple-blue color tone are also referred to as blue roses. Examples of plants of the Rosaceae family having a purple-blue color tone include Aozora, Ondina, Secret Parfum, Murasakiko, and Charles de Some of the names include Goal, Silver Star, Sterling Silver, Seiryu, Turn Blue, Novalis, Purple Time, Blue Bayou, Blue Moon, Blue Light, Blue River, Lovely Blue, Le Ciel Blue, Blue Trail, Something Blue, Misty Purple, Rhapsody in Blue, Blue Chateau, Purple Garden, Violet Hill, Blue Sky, Mikamo, Waltz Time, Fuji Musume, Blue Heaven, Cool, Lapis Lazuli, Kainda Blue, Blue Gravity, Blue Angel, Purple Cloud, Melody Perfume, Angel Face, Prelude, Lady X, Gray Pearl, Lavender Pinocchio, Lilac Charm, Simone, Waltz Time, Gletscher, Twilight, Ivory Tower, Kölner Carnival, Overture, Blue Monday, Cardinal de Richelieu, Stainless Steel, Grand Blue, News, Blue Ribbon, Blue Nile, Twilight, Madame Violet, and Watarase. As the plant containing rosacyanin compounds, one of the above-mentioned plants may be used, or two, three, or four or more may be used in combination. Note that the plants are not limited to the above-mentioned plants, and any plant containing rosacyanin compounds can be used as the extraction material.

[0013] The extract from a plant containing a rosacyanin compound is an extract obtained by extracting a plant containing a rosacyanin compound by any method. The part of the plant used for the extraction may be, for example, a petal, but may also be another part. Note that the extract from a plant containing a rosacyanin compound does not necessarily have to contain the rosacyanin compound itself, as long as the extract exhibits the effect of improving skin transparency.

[0014] Extracts from plants containing rosacyanin compounds can be obtained by methods commonly used for plant extraction. Examples of extraction solvents include water (including hot water), alcohols (e.g., lower alcohols such as methanol, absolute ethanol, and ethanol, or polyhydric alcohols such as propylene glycol, 1,3-butylene glycol, glycerin, and dipropylene glycol), ketones such as acetone, esters such as diethyl ether, dioxane, acetonitrile, and ethyl acetate, organic solvents such as xylene, benzene, and chloroform, animal oils, vegetable oils, supercritical carbon dioxide, and combinations of two or more thereof.

[0015] The extraction time may be, for example, but is not limited to, 0.1 to 96 hours, and the extraction temperature may be, for example, but is not limited to, 1 to 120°C.

[0016] The extracts referred to in the present disclosure include not only extracts obtained from plants as extraction raw materials, but also dilutions or concentrates of the extracts, dried products of the extracts, and crude or purified products thereof. The resulting extracts can be dried using known drying methods (e.g., freeze-drying, vacuum drying, and hot air drying). Furthermore, the resulting extracts can be purified using known purification methods (e.g., ion-exchange resin treatment and activated carbon treatment).

[0017] The skin clarity enhancer of the present disclosure improves skin clarity. According to the Japan Cosmetic Industry Association, "skin clarity" is defined as a state in which the skin appears clear and transparent.

[0018] Skin transparency can be evaluated not only by visual inspection by an expert, but also using indicators such as light transmittance, image analysis, saturation, and hue angle. In the present disclosure, skin transparency may be improved by promoting blood circulation in the skin. Specifically, promoting blood circulation in the skin increases oxidized hemoglobin in the blood, resulting in reduced absorption in the red region and increased red reflectance. Since there is a correlation between blood flow and the visual assessment value of dullness, promoting blood circulation can improve dullness. Furthermore, improving dullness can improve the transparency of the skin and improve skin transparency.

[0019] In addition, blood circulation promotion is measured by the L ＊ Value, indicating redness of the skin a ＊ value, hemoglobin index indicating the amount of hemoglobin in the skin, and HbSO indicating the percentage of oxyhemoglobin ２ Indexes and other indicators can be used for evaluation.

[0020] Therefore, another aspect of the present disclosure may be a blood circulation enhancer having a plant extract containing a rosacyanin compound. The blood circulation enhancer of the present disclosure can be used for various purposes related to promoting blood circulation, other than improving skin clarity.

[0021] Another aspect of the present disclosure may be a body temperature elevating agent containing an extract from a plant containing a rosacyanin compound. By increasing body temperature, blood circulation in the skin is promoted. Therefore, the same effect as the aforementioned effect of improving skin clarity due to the promotion of blood circulation can be expected.

[0022] The body temperature elevating agent of the present disclosure can be used for various applications related to body temperature elevation, other than improving skin clarity. In addition, in the present disclosure, skin clarity may be improved by reducing sebum secretion. Specifically, reducing sebum secretion can prevent pores from opening up and becoming more noticeable due to excessive sebum secretion. It also prevents excess sebum from accumulating dirt in pores, resulting in the formation of keratin plugs, and from the oxidation of sebum due to ultraviolet rays and other factors, resulting in darkening. This can reduce the visibility of skin pores. Furthermore, reducing the visibility of skin pores can improve skin clarity and improve skin clarity.

[0023] The reduction in sebum secretion can be evaluated using indicators such as the amount of sebum and the darkening of pores, and the prominence of pores on the skin can be evaluated using indicators such as the average area, total number, angle standard deviation, circularity, and contrast of pores.

[0024] Therefore, another aspect of the present disclosure may be a sebum secretion reducer having a plant extract containing a rosacyanin compound. The sebum secretion reducer of the present disclosure can be used for various purposes related to sebum secretion reduction, other than improving skin clarity.

[0025] The skin clarity enhancer of the present disclosure may be contained in food, cosmetics, pharmaceuticals, or quasi-drugs. The form of the food containing the skin clarity enhancer of the present disclosure is arbitrary and is not limited. Specific food forms include, for example, general foods, general beverages, supplements, health foods, functional foods and foods for specified health uses such as functional foods and foods for specified uses, soft drinks, tea drinks, energy drinks, alcoholic beverages such as wine, confectioneries, cooked rice, bread, noodles, side dishes, seasonings, etc.

[0026] Furthermore, the dosage forms of cosmetics, pharmaceuticals, and quasi-drugs containing the skin clarity enhancer of the present disclosure are not limited, and specific dosage forms of cosmetics, pharmaceuticals, and quasi-drugs include capsules, tablets, powders, granules, liquids, emulsions, creams, gels, ointments, sheets, mousses, and the like.

[0027] The content of the plant extract containing a rosacyanin compound in the skin clarity enhancer may be 0.01 to 100% by weight, preferably 1 to 90% by weight, more preferably 5 to 80% by weight, and more preferably 10 to 50% by weight, per 100% by weight of the skin clarity enhancer.

[0028] Furthermore, the content of the plant extract containing a rosacyanin compound in the skin clarity enhancer is most preferably 15 to 25 wt %, for example 20 wt %, per 100 wt % of the skin clarity enhancer. When the content of the plant extract containing a rosacyanin compound in the skin clarity enhancer is within this range, the stickiness of the skin clarity enhancer can be suppressed, while suitably improving skin clarity.

[0029] Furthermore, when the skin clarity enhancer of the present disclosure is contained in a food, cosmetic, pharmaceutical, or quasi-drug, the skin clarity enhancer may be contained in the food, cosmetic, pharmaceutical, or quasi-drug so that the above-mentioned content is contained as an extract from a plant containing a rosacyanin compound.

[0030] Furthermore, optional components other than the plant extract containing a rosacyanin compound may be added to the skin clarity enhancer, such as a base material, solvent, preservative, oil, excipient, binder, disintegrant, antiseptic, coating agent, dispersant, fluidizing agent, stabilizer, flavoring agent, colorant, pH adjuster, surfactant, and fragrance.

[0031] The skin clarity enhancer of the present disclosure can be administered to a subject in various dosage forms, but oral administration is preferred. The dosage of the skin clarity enhancer of the present disclosure is determined by taking into consideration the subject's age, sex, weight, usage, dosage, etc. When administered orally, the daily dosage of the plant extract containing a rosacyanin compound in the skin clarity enhancer is preferably 0.1 mg / day to 500 mg / day, more preferably 1 mg / day to 250 mg / day, and more preferably 10 mg / day to 200 mg / day. By administering the amount of the skin clarity enhancer within this numerical range, skin clarity can be suitably improved.

[0032] The skin clarity improving agent of the present disclosure may be administered once or repeatedly over a long or short period of time. The number of administrations is not limited, but may be three times a day, twice a day, once a day, once every two days, once every three days, once a week, once every two weeks, once a month, etc. The administration period is not limited, but may be one day, two days, three days, one week, two weeks, four weeks, six months, one year, or longer.

[0033] Another aspect of the present disclosure relates to a method for improving skin clarity, comprising administering to a subject a skin clarity enhancer comprising an extract from a plant containing a rosacyanin-class compound. Another aspect of the present disclosure relates to the use of an extract from a plant containing a rosacyanin-class compound in preparing the skin clarity enhancer.

[0034] Example 1: Preparation of Formulations Two varieties of blue rose cultivated by Kinjirushi Co., Ltd. were blended to serve as the plant containing rosacyanin compounds. Equal amounts of blue rose petals (4 kg total) were blended, added with five times the amount of water, heated at 90-100°C for 2 hours, and then pressed to obtain an extract. Dextrin (Max 1000 (Matsutani Chemical Industry Co., Ltd.)) was added to the extract in an extract:dextrin ratio of 1:4 (solid content), and the mixture was freeze-dried to obtain an extract powder. Capsules containing the extract powder were prepared as test products. The content of the extract from the plant containing rosacyanin compounds (i.e., the extract) was 20% by weight per 100% by weight of the capsule. Capsules containing only dextrin were also prepared as a control.

[0035] Example 2: Various Tests Various tests (hereinafter simply referred to as "tests") on skin improvement in subjects were conducted using the test product and control product prepared in Example 1. The study protocol and study implementation were reviewed by the Institutional Review Board for ethical and social considerations in accordance with the spirit of the Declaration of Helsinki (amended at the Fortaleza General Assembly in 2013), and were found to be appropriate. The origin, purpose, and methods of the study, the handling of personal information regarding the study results, the subjects' rights, and consultation and compensation methods in the event of adverse events were explained to the subjects, and the study was conducted after confirming in writing that they would participate in the study of their own free will. Any substantial deviations from the study protocol required approval from the Institutional Review Board. (1) Subject Selection Forty-eight subjects who self-reportedly met the following inclusion criteria and did not violate the following exclusion criteria were selected as study subjects.

[0036] Inclusion criteria: - Healthy Japanese women aged 40 years or older and 50 years or younger at the time of obtaining consent - Those with skin types III and IV (according to the Fitzpatrick classification) - Those who are aware of dry skin Exclusion criteria: - Those suffering from skin diseases such as psoriasis - Those suffering from skin diseases such as atopic dermatitis - Those taking or applying medicines that may affect the test results - Those with contact allergies or those at risk of showing allergic symptoms - Those currently seeing a dermatologist - Those with eczema, rash, sunburn, blemishes, scratch marks, etc. on the test site - Those who are pregnant or may be pregnant, or those who are breastfeeding - Those who are participating in other tests that will interfere with this test at the start of the test, or those who plan to participate in other tests that will interfere with this test during the planned test period - Those with tattoos, tattoo stickers, body paint, etc. on the test site - Those who have undergone chemical peels, laser treatments, light irradiation treatments, skin injections, surgical treatments, or beauty treatments on the test area within the four weeks prior to the start of the test. - Those who are deemed unsuitable for participation in the test by the person in charge of the test.

[0037] (2) Intake: Using stratified randomization, subjects were assigned to a test product intake group and a control product intake group. Subjects took the prescribed amount (1 capsule) of the test product or control product at night before going to bed. The intake period was 4 weeks, and subjects took the test product or control product continuously for 4 weeks.

[0038] (3) Evaluation or Measurement A double-blind test was conducted to compare the groups receiving the test product and the control product. Evaluation or measurement was conducted twice, before the test and after four weeks of continuous use of the test product or the control product. Before the test and after four weeks of continuous use of the test product or the control product, the subjects washed their faces with cleansing cream and face wash, and then spent approximately 20 minutes resting in a room maintained at a temperature of 21.0±0.3°C and a relative humidity of 45.0±2.0%. After allowing the skin to acclimate to the test environment, the following evaluation items were evaluated or measured. - Transparency evaluation using visual judgment - Sebum amount - Hemoglobin index using a colorimeter - Body surface temperature - Skin redness (a ＊ ) ・Dullness assessment using visual assessment ・Dark pore assessment using visual assessment ・Pore analysis using replica images (4) Changes and missing data in measurement status If there is a possibility that a subject will withdraw from the study due to health status or personal wishes, the subject's health status and wishes will be given priority in accordance with the Declaration of Helsinki. In addition, if it becomes unavoidable to collect some data due to these or other reasons, it will be treated as missing data.

[0039] Additionally, if any of the following occurs, the subject will be subject to a case review meeting, and unless there are special reasons, the subject will be excluded from the study analysis (reporting): - If the observation date is delayed by more than one week - If a significant violation of the instructions in the subject management matters is discovered during the study period - If a major problem arises with the reliability of the data due to problems with the test - If the number of days of intake (if the specified daily intake amount is not met) exceeds 15% of the planned number of days of intake - If it is found that the entry criteria have been violated and that the subject meets the exclusion criteria - If there are any other clear reasons that it is appropriate to treat the subject as a dropout

[0040] (5) Statistical analysis This study began with 48 subjects, and ultimately, 44 subjects who did not drop out or were excluded from the analysis were included in the analysis. For reference, statistical analysis was performed using an unpaired t-test between the test product intake group and the control product intake group at each measurement time point of the instrumental measurements, and a Wilcoxon rank sum test between the test product intake group and the control product intake group at each measurement time point.

[0041] (6) Results (A) Evaluation of Skin Transparency Using Visual Assessment After the skin was allowed to acclimate to the test environment, an experienced assessor visually assessed the skin transparencies of the subjects' faces using a 5-point scale (1: no sense at all, 2: little sense, 3: normal, 4: some sense, 5: considerable sense). The results are shown in Figure 1. In Figure 1, a higher value indicates a more translucent skin.

[0042] The relative skin clarity score after 4 weeks of continuous use, where the skin clarity measured visually before the test was set at 100%, showed a tendency to be higher in the test product group compared to the control product group. Therefore, it was thought that administration of the test product improved skin clarity.

[0043] (B) Sebum Amount After the skin was acclimatized to the test environment, the sebum amount was measured using a Sebumeter SM815 (Courage+Khazaka, Germany). The results are shown in Figure 2. In Figure 2, a larger value indicates a larger sebum amount.

[0044] The relative sebum volume after 4 weeks of continuous use, with the sebum volume before the test taken as 100%, showed a significantly lower value in the test product group compared to the control product group. Therefore, it was thought that administration of the test product reduced the sebum volume.

[0045] (C) Hemoglobin Index Using a Colorimeter After the skin was acclimatized to the test environment, the hemoglobin index was measured using a colorimeter CM-700d (Konica Minolta, Japan). The results are shown in Figure 3. In Figure 3, a larger hemoglobin index value indicates more erythema on the skin or a larger blood flow (better blood circulation).

[0046] The hemoglobin index relative to the pre-test hemoglobin index (100%) was significantly higher in the test group than in the control group after 4 weeks of continuous administration. Therefore, it was thought that administration of the test product promoted blood circulation.

[0047] (D) Body surface temperature After the skin was acclimatized to the test environment, the body surface temperature of the face was measured using a non-contact radiation thermometer (CISE, Muranaka Medical, Japan). The results are shown in Figure 4. In Figure 4, a larger value indicates a higher body surface temperature.

[0048] The relative body surface temperature after 4 weeks of continuous use, with the body surface temperature before the test taken as 100%, showed significantly higher values ​​in the test product group compared to the control product group. Therefore, it is believed that the administration of the test product caused an increase in body surface temperature.

[0049] (E) Skin redness measured using a color difference meter (a ＊ After the skin was allowed to adapt to the test environment, redness (a) of the skin was measured using a color difference meter CM-700d (Konica Minolta, Japan). ＊ The results are shown in Figure 5. In Figure 5, the redness of the skin (a ＊ ) indicates that the skin is less red.

[0050] Redness of the skin before the test (a ＊ ) was used for 4 weeks, with the redness of the skin (a ＊ The relative values ​​of the test product group were significantly higher than those of the control group. Therefore, it was thought that administration of the test product promoted blood circulation.

[0051] (F) Evaluation of dullness using visual judgment After the skin was acclimatized to the test environment, an experienced evaluator visually evaluated the dullness of the skin on the face of each subject using a three-point scale (1: not dull, 2: neither dull nor dull, 3: dull). The results are shown in Figure 6. In Figure 6, a smaller value indicates less dullness of the skin.

[0052] The relative dullness score after four weeks of continuous use, where the visual assessment was taken as 100%, showed a tendency for the test product intake group to show lower scores than the control product intake group. Therefore, it is thought that administration of the test product may improve dullness.

[0053] (G) Evaluation of dark pores using visual assessment After the skin was acclimatized to the test environment, an experienced assessor visually assessed the dark pores on the subject's face using a three-point scale (1: inconspicuous, 2: neutral, 3: noticeable). The results are shown in Figure 7. In Figure 7, a smaller value indicates less noticeable dark pores.

[0054] The relative values ​​of darkening of pores after 4 weeks of continuous use, where visual assessment of darkening of pores was taken as 100%, showed a tendency for the test product intake group to show lower values ​​than the control product intake group. Therefore, it is thought that administration of the test product may improve darkening of pores.

[0055] (H) Pore analysis using replica images After the skin was acclimatized to the test environment, a replica of the cheek was taken using SKIN CAST (Raptor Survey Institute, Japan), a hydrophilic vinyl silicone impression agent, and the replica was photographed with an i-Scope. The total number of pores and the contrast in brightness in the photographed replica images were analyzed using an image analysis application. The area of ​​one pore was 0.06 mm ２ These pores were defined as the pores in the test. The total number of pores and the contrast in brightness within the image analysis range (9.5 x 7.1 mm) were analyzed. The results are shown in Figures 8A and 8B. Note that in Figures 8A and 8B, the smaller the total number of pores, the fewer the pores. Also, the smaller the contrast in brightness between pores, the less noticeable the pores.

[0056] The relative value of the total number of pores after four weeks of continuous use, with the number of areas recognized as pores on the replica before the test being 100%, showed a significantly lower value in the test product intake group compared to the control product intake group.

[0057] Furthermore, the relative value of the total number of pores after 4 weeks of continuous use, where the difference in brightness of the pores on the replica before the test was taken as 100%, showed a tendency for the test product intake group to show significantly lower values ​​compared to the control product intake group. Therefore, it is thought that the administration of the test product made the pores less noticeable.

Claims

1. A skin clarity enhancer containing extracts from plants containing rosacyanin compounds.

2. The agent for improving skin clarity according to claim 1, wherein the improvement in skin clarity is achieved by promoting blood circulation in the skin.

3. The agent for improving skin clarity according to claim 1, wherein the improvement in skin clarity is achieved through a reduction in sebum secretion.

4. The skin clarity enhancer according to claim 2, which improves dull skin by promoting blood circulation in the skin.

5. The skin clarity improver according to claim 3, wherein the reduction in sebum secretion reduces the visibility of skin pores.

6. A skin clarity improving agent described in any one of claims 1 to 5, which is administered orally.

7. A food for improving skin clarity, comprising the skin clarity improver according to any one of claims 1 to 5.

Images